Ginsenoside Ro

Overview

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca 2+ -antagonistic antiplatelet effect with an IC 50 of 155 μM. Ginsenoside Ro reduces the production of TXA 2 more than it reduces the activities of COX-1 and TXAS.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Hypertension | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > Prostaglandin Receptor

Product Information

• Catalog No.: HY-N0607
• CAS No.: 34367-04-9
• Molecular Formula: C48H76O19
• Molecular Weight: 957.11
• Purity: 99.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution
• Availability: In-stock

Source

Original product source